Charles River has announced its intention to acquire non-clinical CRO MPI Research for $800m. This follows a string of acquisitions within the Integrated Drug Discovery Services (IDDS) Space at the start of 2018, including Spectris Plc's acquisition of Manchester-based Concept Life Sciences, Charles River's acquisition of Bristol-based KWS Biotest and Eurofins' acquisition of Chelmsford-based CRO Selcia.
For a wider discussion of what's driving interest in this area, particularly in the UK, see our discussion with PharmaField from earlier this month:
Charles River Laboratories International says it is en route to ‘double its size in five years’ with the acquisition of non-clinical CRO MPI Research. The $800m (€648m) acquisition will add drug safety, testing, and discovery services to Charles River’s offerings. According the CRO Jim Foster, the site will help Charles River meet growing demand. As pharma companies increasingly rely on outsourced services to improve efficiency and access to expertise they no longer maintain in-house, Charles River need additional capacity to accommodate the demand, he told investors earlier today. “For that reason, the acquisition of MPI Research is particularly opportune.” The acquisition of MPI – which shares a similar client base of mostly small and medium-sized biotech clients – expands Charles River’s capabilities in a few new areas, and boosts current offerings.